BSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,138.70
- Market cap
- ₹5,244 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 39.3×Sector 48.6×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Earnings Call Transcript: Key Takeaways
Senores delivered record quarterly revenue and EBITDA, driven by US portfolio expansion and regulated market growth.
- Call
- Guides 40% growth
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Other regulatory approval announcements
All →Xtglobal Infotech Regulatory Approval
XTGlobal received RBI approval for a ₹0.10 Crore (EUR 10,000) equity investment in its Irish subsidiary. The initial capital supports its European expansion plans.
- Value
- ₹0.10 Cr
Regal Entertainment & Consultants Regulatory Approval
Regal Entertainment received RBI approval for Satbir Singh's appointment as Executive Director. Shareholder approval is still pending, with the term running to April 4, 2028.
Biocon Regulatory Approval
Biocon received U.S. FDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Perjeta, its fifth oncology biosimilar approved in the US. A global settlement with Genentech sets the earliest US launch in Q3 2028.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Binimetinib tablets, securing 180 days of generic drug exclusivity for the product.
United Breweries Regulatory Approval
United Breweries received BIADA's final order restoring its 42-acre Patna land allotment under the Amnesty Policy 2025, subject to conditions. Commercial production milestones must be met within 24 months.
Bhageria Industries Regulatory Approval
Bhageria Industries received EDQM attestation of GMP inspection for its Vapi facility, confirming EU GMP compliance for Dexamethasone under CEP No. 2024-138. No monetary value is disclosed.